Department of Internal MedicineHenry Ford HospitalDetroitMIUSA.
Division of CardiologyDepartment of MedicineHenry Ford HospitalDetroitMIUSA.
Hepatol Commun. 2020 Oct 6;5(1):24-32. doi: 10.1002/hep4.1586. eCollection 2021 Jan.
Respiratory failure is the most common cause of death in patients with corona virus disease 2019 (COVID-19). There have been many investigations to determine predictors of bad outcomes in patients with this illness. Liver enzyme elevation has been described in hospitalized patients with severe COVID-19; however, little is known about the significance of liver injury regarding outcomes. We conducted a retrospective chart review of 348 patients admitted with COVID-19 in our quaternary care center. Liver injury on admission was defined based on the laboratory cutoff of aspartate aminotransferase >35 IU/L and/or alanine aminotransferase >52 IU/L. Patients were divided into two cohorts based on the presence or absence of liver injury. These cohorts were compared to assess differences in presentation, complications, and outcomes. The primary outcome was respiratory failure requiring intubation, and the secondary outcome was in-hospital mortality. The presence of new onset liver enzyme elevation on presentation was associated with increased severity of illness, need for mechanical ventilation, and mortality. Presence of liver injury increased the chance of acute hypoxic respiratory failure requiring mechanical ventilation by 1.79 times. The degree and timeline of liver enzyme elevation during hospitalization corresponded with elevations of other inflammatory markers. : Liver injury appears to correlate with the inflammatory syndrome caused by COVID-19, with the degree of liver injury corresponding with severity of inflammation. We suggest early and continued monitoring of liver enzymes as they can be useful to identify patients who may need early escalation of care.
呼吸衰竭是 2019 年冠状病毒病(COVID-19)患者死亡的最常见原因。已经有许多研究旨在确定患有这种疾病的患者不良预后的预测因素。在患有严重 COVID-19 的住院患者中已经描述了肝酶升高;然而,关于肝损伤与预后的关系知之甚少。我们对在我们的四级护理中心住院的 348 例 COVID-19 患者进行了回顾性图表审查。入院时的肝损伤定义为天门冬氨酸转氨酶(AST)>35IU/L 和/或丙氨酸转氨酶(ALT)>52IU/L。根据有无肝损伤将患者分为两组。比较这些队列以评估表现、并发症和结局的差异。主要结局是需要插管的呼吸衰竭,次要结局是住院死亡率。入院时新出现的肝酶升高与疾病严重程度增加、需要机械通气和死亡率相关。肝损伤的存在使急性低氧性呼吸衰竭需要机械通气的可能性增加了 1.79 倍。住院期间肝酶升高的程度和时间与其他炎症标志物的升高相对应。:肝损伤似乎与 COVID-19 引起的炎症综合征相关,肝损伤的程度与炎症的严重程度相对应。我们建议早期和持续监测肝酶,因为它们可以帮助识别可能需要早期升级治疗的患者。